



Heart Failure Dashboard

Catholic Health

	Data Through	Current Month	Q3 2026	YTD 2026	2025	"Reference Values"
<i>Discharge Medications in 4 GDMT Classes</i>						NEJM, ESHF, 11/20-5/22, 2/3 Class 3 or 4 - AF ablation in CHF study
MRA (spironolactone, etc)	Sep-26	21.7%	25.5%	21.4%	20.6%	50%
SGLT2i	Sep-26	33.3%	37.0%	34.2%	32.7%	25%
RAS Blockers ACEI/ARB/ARNI - <u>any</u> dose	Sep-26	21.7%	25.5%	20.2%	20.2%	38% ACE/ARB 63% ARNI
Beta Blocker - <u>any</u> dose	Sep-26	45.0%	44.0%	40.3%	37.7%	100% on RAS blockers 95%
<i>Patient Type - informational</i>						
HFpEF (EF>50%)	Sep-26	53.3%	50.9%	48.7%	44.5%	
<i>LOS</i>						
Average Length of Stay - days	Sep-26	5.1	4.6	5.5	5.8	
<i>Quality Improvement</i>						
CHF Order Set Compliance (%)	Sep-26	36.7%	44.4%	44.0%	46.1%	
<i>Readmissions</i>						
All Cause Readmissions (%)	Aug-26	17.5%	15.4%	15.3%	14.6%	

Updated: 10/6/2026